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Methotrexate (MTX)-based chemotherapy extends survival in patients with primary brain lymphomas, but it is not clear whether
multiagent chemotherapy is superior to MTX alone. Treatment options for patients with recurrent primary brain lymphoma are
limited; there is no standard second-line chemotherapy. New chemotherapeutic agents with clear activity in brain lymphoma are
needed for treatment of recurrent disease. We report the results of a phase II trial assessing activity of the alkylating agent
temozolomide in immunocompetent patients with recurrent primary brain lymphomas, previously treated with high-dose MTX-
containing chemotherapy and/or radiotherapy. A median of two courses (range 1–12) of temozolomide 150mgm
 2day
 1, for 5
days every 4 weeks was administered to 36 patients yielding nine complete and two partial responses (response rate: 31%; 95%
confidence interval 16–46%). One-year survival was 31% (95% confidence interval 16–46%). Toxicity was negligible. We conclude
that temozolomide is active in recurrent primary brain lymphomas and should further be evaluated in this disease, perhaps in
combination with MTX as initial treatment.
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There is general consensus that high-dose methotrexate (HD-
MTX) is the cornerstone of the initial treatment of primary central
nervous system lymphomas (PCNSL) (Reni et al, 1997; Ferreri
et al, 2000, 2002, 2003; Reni and Ferreri, 2004a). However, for
most patients, this remains an incurable disease, and attempts
to improve survival with combinations of HD-MTX and other
chemotherapeutic agents have not convincingly been shown to be
superior to MTX alone (Ferreri et al, 2002; Ferreri et al, 2003).
Although a recent retrospective analysis has suggested that the
addition of cytarabine to HD-MTX might be an independent
positive prognostic factor for improved survival (Ferreri et al,
2002), this observation has not been confirmed in a randomised
phase III trial, in part because of the difficulties associated with
conducting large prospective studies in such a rare disease. There
are few agents with demonstrable activity in primary brain
lymphoma. Most active agents used for extracerebral non-
Hodgkin’s lymphomas do not penetrate the blood–brain barrier
at sufficient concentration to be effective against primary brain
lymphoma, and agents that do penetrate the CNS have generally
not been very effective, or have caused unacceptable toxicities
(Ferreri et al, 2003; Reni and Ferreri, 2004a). As salvage therapy
improves survival in PCNSL (Reni et al, 1999), we have chosen to
prospectively evaluate new drugs in patients with relapsed or
refractory disease in an attempt to identify promising agents with
activity in primary brain lymphoma. This paper reports the final
results of a phase II trial assessing the activity of a single-agent
temozolomide for patients with recurrent PCNSL. Preliminary
results of this trial and our rationale for choosing temozolomide
for evaluation in PCNSL have been reported elsewhere (Reni et al,
2004b).
MATERIALS AND METHODS
Patients were eligible for enrolment in this trial provided they met
the following criteria: age 417 years, failure following initial
treatment with HD-MTX and or radiotherapy, histologic diagnosis
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sof PCNSL, presence of at least one bi-dimensionally measurable
target lesion, negative HIV serology, ECOG performance status
(PS) o4, adequate bone marrow (plateletX100000mm
3, haemo-
globin X10gdl
 1, absolute neutrophil count X1500mm
3), renal
(serum creatinine X2 times upper limit of normal (UNL)) and
hepatic function (SGOT/SGPT X3 times UNL, bilirubin and
alkaline phosphatase X2 times UNL). The protocol was reviewed
and approved by local ethics committees. All participating patients
provided written informed consent. The study was conducted in
agreement with the Declaration of Helsinki. Temozolomide was
administered at 150mgm
 2day
 1, for 5 days every 4 weeks until
progression of disease (PD), unacceptable toxicity or patient’s
refusal. Temozolomide was administered for a maximum of six
cycles when the best response was stabilisation of the disease (SD).
In patients with objective response, at least two cycles of
temozolomide were administered after maximum radiographic
response. Criteria for dose modification in the event of toxicity
have been described previously (Reni et al, 2004b). Briefly, for
absolute neutrophil count X1500mm
 3 or platelets
X100000mm
 3 on the intended day of re-treatment, the start of
the next cycle was delayed until haematopoietic recovery for a
maximum of 2 weeks. For grade 3 or 4 toxicity, dosage
for subsequent cycles of temozolomide was reduced to 100mgm
 2.
Pretreatment evaluation included whole body computed tomo-
graphy (CT) scan, whole brain CT (N¼6) or magnetic resonance
(MR; N¼30) scan, and, whenever possible, CSF examination with
cell count and cytology. Whole brain CT or MR scans were
repeated every 2 months during chemotherapy and every 3 months
thereafter. Toxicity was graded by the National Cancer Institute
Common Toxicity Criteria version 2.0 and response to treatment
was assessed according to the criteria of MacDonald et al (1990).
The best response recorded from the start of the treatment was
considered. The progression-free and overall survival were
measured from initiation of treatment. All analyses were
performed on an intent-to-treat basis. The principal end point of
this trial was the objective radiographic response rate to
temozolomide. The maximum response rate considered of low
interest was 15% and the minimum response rate considered
of interest was 35%. The target enrolment (a¼0.05; b¼0.10) was
estimated to be 38 patients, among whom at least 10 objective
responses were necessary to declare temozolomide active against
PCNSL.
RESULTS
After enrolment of 36 patients, nine complete responses (25; 95%
confidence interval 11–39%) and two partial responses (6; 95%
confidence interval 0–14%) were observed. The study was closed
at this time as the target of 10 objective responses was achieved.
Table 1 Summary of patient characteristics at baseline
Patient Age Gender PS Histotype First line
Number
of lines Lesions RT Failure TFTF OR Duration Survival
1 66 Male 3 DLC MVP 2 Single + R 5 CR 70.0+ 74.0+
2 54 Male 2 DLC MVP 1 Multiple + R 19 PR 2.5 2.5
3 61 Female 0 DLC MA 1 Multiple   R 10 PD 2.0
4 60 Male 2 DLC MBAVm 1 Multiple + R 23 ED 1.5
5 57 Male 3 DLC MATI 1 Single   PD 4 PD 3.5
6 52 Male 3 DLC CVOD/BVAM 1 Multiple + R 11 ED 1.0
7 62 Female 0 DLC MATI 1 Multiple + R 14 PD 1.5
8 54 Male 1 LP M 1 Multiple + PD 10 SD 16.5 54.5+
9 68 Male 2 DLC none 0 Multiple + R 99 PD 4.5
10 64 Male 1 DLC MATI 1 Single + R 12 SD 2.0 2.0
11 51 Male 1 DLC MA 1 Multiple + R 39 CR 2.0 19.0
12 54 Female 2 DLC F-MACHOPn 2 Multiple + R 130 PD 3.5
13 54 Male 2 DLC MAI 4 Single + R 28 PD 2.5
14 64 Female 1 DLC MVP 1 Multiple + R 24 PD 16.0
15 61 Female 2 UN M 1 Single + R 19 CR 17.5+ 18.0+
16 62 Male 0 DLC MVP 1 Single   R 14 PD 27.5
17 54 Female 1 DLC VPAL 1 Multiple + R 20 SD 9.5 9.5
18 81 Male 1 UN MVP 1 Single   R 44 CR 6.0 22.5+
19 48 Male 2 UN MVP 1 Multiple + PD 6 ED 1.0
20 66 Male 2 DLC A 1 Multiple + R 48 ED 1.0
21 47 Male 0 DLC A 1 Single + R 14 SD 5.0 25.5+
22 69 Male 4 DLC MA 1 Single + R 38 CR 4.5 7.0
23 56 Female 3 DLC MA 1 Multiple + R 18 PD 0.5
24 75 Male 3 DLC none 0 Multiple + R 21 PR 6.5 9.0
25 59 Female 3 DLC MATI 1 Multiple + PD 9 PD 2.0
26 34 Male 2 DLC MA,P, PBSCT 3 Multiple + PD 20 CR 1.0 5.5
27 36 Male 2 DLC MABET 2 Multiple + PD 1 ED 1.0
28 58 Male 3 DLC MATI 1 Single + R 9 ED 1.5
29 51 Female 2 DLC M, Me, N, R,
PBSCT
1 Multiple   R 20 PD 2.0
30 59 Female 2 DLC MATI 1 Multiple + R 8 PD 5.0
31 73 Female 3 DLC MATI 1 Multiple + R 28 CR 20.0+ 22.0+
32 54 Female 3 DLC MATI 1 Multiple + R 54 CR 9.5 13.5
33 64 Male 2 DLC MATI 1 Multple + R 12 PD 2.5
34 65 Male 3 HG MA 2 Multiple + PD 8 CR 7.0+ 14.0+
35 72 Male 2 DLC — — Single + PD 8 SD 5.0 5.5
36 65 Male 2 DLC M 1 Multiple + R 10 PD 1.5
Abbreviations: A¼cytarabine; B¼carmustine; CR¼complete response; D¼dexamethasone; DLC¼diffuse large B cells; E¼etoposide; ED¼early death; F¼fluorouracil;
HG¼high grade; I¼idarubicin; LP¼lymphoplasmacytic; Me¼melphalan; M¼methotrexate; N¼novantrone; O¼doxorubicin; OR¼overall response; P¼procarbazine;
PBSCT¼peripheral blood stem cell transplantation; PD¼progression; Pn¼prednisone; PR¼partial response; PS¼performance status; R¼recurrence; Ri¼rituximab;
RT¼radiotherapy; SD¼stable disease; T¼thiotepa; TFTF¼time to first treatment failure; UN¼unclassified; V¼vincristine.Vm: teniposide; L¼lomustine.
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treatment are summarised in Table 1. Twenty-eight patients (78%)
had a first recurrence of PCNSL and eight had multiple recurrent
disease having failed other salvage regimens. Median age was 60
years (range 34–81) and median ECOG performance status was 2
years (range 0–4). Median complete response duration was 7
months (range 1–70þ) and four patients are currently free of
disease at 7, 17.5, 20 and 70 months. All responses but one were
observed among patients who were monitored by MR imaging.
One complete response was observed among six patients
monitored by CT scan and this lasted 6 months. Five patients
had SD, 14 had PD and six died before response could be
evaluated, probably due to PD. The clinical course of the five
patients with SD was variable, likely owing to further therapy
whose details were not available after PD in two patients (nos. 8
and 21) and to lymphoplasmacytic histology in one patient (no. 8).
Since completion of our trial, new response criteria for PCNSL
have been suggested (Abrey et al, 2005). No change in response
rates was observed when these criteria were applied to our series.
Five patients were alive at a median follow-up of 22 months (range
14–74) after initial failure, two patients were lost to follow-up with
PD at 22.5 and 25.5 months and 29 patients had died. Median
progression-free survival was 2.8 months (interquartile range 1–8
months), median overall survival was 3.9 months (interquartile
range 1.7–16 months) and 1-year overall survival was 31% (95%
confidence interval 16–46%). Altogether, 125 cycles (median 2;
range 1–12) of temozolomide were delivered. Toxicity was mild;
two patients had one episode of grade 4 neutropenia, associated in
one case with grade 4 thrombocytopenia, and one patient had
grade 3 vomiting in a single cycle.
DISCUSSION
The final results of this trial of temozolomide monotherapy for
recurrent PCNSL confirm and extend our preliminary observations
(Reni and Ferreri, 2004a). As this is the first phase II trial of
salvage monochemotherapy for PCNSL, we arbitrarily chose a
minimum response rate of 35% for a drug to be considered of
interest. We observed an objective response rate of 31%, most of
which were complete responses, in a heavily pretreated patient
population, with poor PS. These results suggest that temozolomide
is an active agent against PCNSL. Recent reports of outcomes for
recurrent PCNSL using combined chemotherapy (Arellano-Rodri-
go et al, 2003; Tyson et al, 2003), single agent topotecan (Fischer
et al, 2006) or combined chemo-immunotherapy (Enting et al,
2004) have observed responses similar to those we observed with
temozolomide. In these studies, reported response rates were 33–
53% and 1-year survivals were 25–58% (Arellano-Rodrigo et al,
2003; Tyson et al, 2003; Enting et al, 2004; Fischer et al, 2006) with
better results observed in the smallest retrospective series, which
included almost exclusively (93%) recurrent patients (Enting et al,
2004). The conclusions one can draw from these series are limited
because in most cases less than 20 patients were reported
(Arellano-Rodrigo et al, 2003; Enting et al, 2004), most series
were retrospective (Tyson et al, 2003; Enting et al, 2004), used
heterogeneous salvage treatment (Tyson et al, 2003), heteroge-
neous drug dose and schedule (Enting et al, 2004) or included
patients with systemic recurrence (Fischer et al, 2006). Further-
more, the series that presented response and survival data superior
to those reported here included more patients with favourable
prognostic factors (younger age, better PS) or had many patients
who had been treated with chemotherapy alone. Patients with
PCNSL who relapse following chemotherapy-only regimens that
avoid radiotherapy generally have more chemosensitive disease
and better responses to salvage chemotherapy. These patients are
candidates to salvage irradiation as well, which may influence
overall survival. The use of 1-week-on 1-week-off temozolomide
schedule combined with the anti-CD20 monoclonal antibody
rituximab achieved a 53% objective response rate and a median
survival of 14 months in a retrospective small series that was
biased by many of the above-mentioned factors (Enting et al,
2004). However, the short median PFS (2.2 months) observed in
this series suggests that overall survival was influenced more by
treatment administered after temozolomide–rituximab failure
than by the study combination itself. Furthermore, the median
PFS obtained by temozolomide and rituximab in this study is
similar to our experience with conventionally administered
temozolomide monotherapy, suggesting that no additional benefit
is derived by the addition of rituximab or from a dose
intensification of temozolomide. We believe that temozolomide
is an excellent candidate agent for further development as a
treatment for PCNSL for several reasons: it is well tolerated, even
in elderly or poor PS patients; it exhibits additive cytotoxic activity
with radiotherapy and in fact may be a radiosensitising agent; and
its noncumulative and modest toxicity makes it potentially useful
as an agent for induction, consolidation and maintenance therapy.
The present trial represents a simple and effective model for
evaluating single agents in this rare disease. This strategy can be
employed to identify quickly active new agents that can subse-
quently be incorporated into therapeutic approaches to the initial
management of PCNSL aimed at improving disease control and
survival.
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